YU55900A - Postupak za sintezu inhibitora hiv proteaze - Google Patents

Postupak za sintezu inhibitora hiv proteaze

Info

Publication number
YU55900A
YU55900A YU55900A YU55900A YU55900A YU 55900 A YU55900 A YU 55900A YU 55900 A YU55900 A YU 55900A YU 55900 A YU55900 A YU 55900A YU 55900 A YU55900 A YU 55900A
Authority
YU
Yugoslavia
Prior art keywords
synthesis
protease inhibitors
hiv protease
isobutylbenzenesulphonamido
furyl
Prior art date
Application number
YU55900A
Other languages
English (en)
Inventor
Emile Al-Farhan
David Deininger
Stephen Mcghie
John O'callaghan
Mark Stuart Robertson
Keith Rodgers
Stephen Rout
Hardev Singh
Roger Denis Tung
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU55900A publication Critical patent/YU55900A/sh
Publication of RS49954B publication Critical patent/RS49954B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Poboljšan postupak za sintezu (3S)-tetrahidro-3-furil N-[(1S,2R)-3-(4-amino-N-izobutilbenzensulfonilamido)-1-benzil-2-hidroksipropil] karbamata koji se sastoji iz četiri koraka, polazeći od jedinjenja formule (A), i njegovi novi intermedijari.[An improved process for the synthesis of (3i(S))-tetrahydro-3-furyl i(N)-[(1i(S),2i(R))-3-(4-amino- i(N)-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl]carbamate comprising four steps from the compound of formula (A) and a novel intermediate thereto.
YUP-559/00A 1998-03-20 1999-03-18 Postupak za sintezu inhibitora hiv proteaze RS49954B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
YU55900A true YU55900A (sh) 2003-02-28
RS49954B RS49954B (sr) 2008-09-29

Family

ID=10828884

Country Status (32)

Country Link
US (1) US6281367B1 (sh)
EP (1) EP1066276B1 (sh)
JP (1) JP3363439B2 (sh)
KR (1) KR100555278B1 (sh)
CN (1) CN1308319C (sh)
AP (1) AP1226A (sh)
AT (1) ATE242772T1 (sh)
AU (1) AU751534B2 (sh)
BR (1) BR9908970A (sh)
CA (1) CA2324217C (sh)
CZ (1) CZ299193B6 (sh)
DE (1) DE69908761T2 (sh)
DK (1) DK1066276T3 (sh)
EA (1) EA003022B1 (sh)
EE (1) EE04750B1 (sh)
ES (1) ES2203090T3 (sh)
GB (1) GB9805898D0 (sh)
HK (1) HK1032047A1 (sh)
HR (1) HRP20000609B1 (sh)
HU (1) HUP0105439A3 (sh)
ID (1) ID26587A (sh)
IL (1) IL138127A (sh)
IS (1) IS2273B (sh)
NO (1) NO317648B1 (sh)
NZ (1) NZ506563A (sh)
PL (1) PL201810B1 (sh)
PT (1) PT1066276E (sh)
RS (1) RS49954B (sh)
SK (1) SK283939B6 (sh)
TR (1) TR200002698T2 (sh)
WO (1) WO1999048885A1 (sh)
ZA (1) ZA200004482B (sh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843946A (en) 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
EP2314564A3 (en) * 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
HUE034389T2 (en) 2002-05-16 2018-02-28 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
AP3551A (en) 2010-01-27 2016-01-18 Viiv Healthcare Co Antiviral therapy
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5843946A (en) * 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða

Also Published As

Publication number Publication date
EP1066276A1 (en) 2001-01-10
IS2273B (is) 2007-07-15
CA2324217A1 (en) 1999-09-30
ZA200004482B (en) 2001-11-28
CN1308319C (zh) 2007-04-04
CZ299193B6 (cs) 2008-05-14
EA003022B1 (ru) 2002-12-26
HUP0105439A2 (en) 2002-06-29
IS5605A (is) 2000-08-29
CZ20003457A3 (cs) 2001-04-11
CN1293668A (zh) 2001-05-02
WO1999048885A1 (en) 1999-09-30
EP1066276B1 (en) 2003-06-11
GB9805898D0 (en) 1998-05-13
HRP20000609A2 (en) 2001-04-30
AP1226A (en) 2003-11-21
CA2324217C (en) 2008-02-19
AP2000001911A0 (en) 2000-09-30
KR100555278B1 (ko) 2006-03-03
RS49954B (sr) 2008-09-29
NO20004664L (no) 2000-09-19
SK283939B6 (sk) 2004-05-04
US6281367B1 (en) 2001-08-28
KR20010042022A (ko) 2001-05-25
ATE242772T1 (de) 2003-06-15
TR200002698T2 (tr) 2000-12-21
HK1032047A1 (en) 2001-07-06
NO317648B1 (no) 2004-11-29
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
AU2947599A (en) 1999-10-18
EA200000859A1 (ru) 2001-04-23
ID26587A (id) 2001-01-18
DK1066276T3 (da) 2003-10-06
DE69908761T2 (de) 2004-02-19
AU751534B2 (en) 2002-08-22
JP3363439B2 (ja) 2003-01-08
EE04750B1 (et) 2006-12-15
PL201810B1 (pl) 2009-05-29
EE200000568A (et) 2002-02-15
JP2002507609A (ja) 2002-03-12
DE69908761D1 (de) 2003-07-17
NZ506563A (en) 2003-05-30
PT1066276E (pt) 2003-10-31
PL342602A1 (en) 2001-06-18
IL138127A (en) 2003-10-31
NO20004664D0 (no) 2000-09-19
HRP20000609B1 (en) 2006-05-31
ES2203090T3 (es) 2004-04-01
SK13732000A3 (sk) 2001-08-06
BR9908970A (pt) 2000-11-28

Similar Documents

Publication Publication Date Title
MX9703564A (es) Inhibidores de proteasa multicatalitica.
NO305478B1 (no) Hydroksyetylaminosulfonamider som retrovirale proteasehemmere
AU575668B2 (en) N - acylpyrrolidine compound
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
TW223630B (en) Retroviral protease inhibitors
YU55900A (sh) Postupak za sintezu inhibitora hiv proteaze
MY116862A (en) New processes for preparing pesticidal intermediates
ES2167419T3 (es) Procedimiento de fabricacion de un epoxido.
PL325954A1 (en) Guanidinic protease inhibitors
BG104243A (en) Method for the synthesis of quinoline derivatives
BG105766A (en) New process for preparing pesticidal intermediates
ZA945194B (en) Process for making HIV protease inhibitors
IL158356A0 (en) Benzoheterocycles
BG104073A (en) Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds
GB9909229D0 (en) Enantiomers of mercapto lactones and processes for their synthesis
MXPA04003086A (es) Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.
EA199700235A1 (ru) Способ получения ингибитора протеазы вич из (2-s)-4-пиколил-2-пиперазин-трет-бутилкарбоксамида
CA2175420A1 (en) Process for the preparation of optionally 2-substituted 5-chloroimidazole-4-carbaldehydes
CA2117034A1 (en) Process for the production of 2-substituted-5-chlorimidazole-4-carbaldehydes
TW200611691A (en) Retroviral protease inhibiting compounds
DK0675880T3 (da) Quinolondisulfider som mellemprodukter
MX9605794A (es) Intermediario para preparar un compuesto farmaceuticamente activo.
WO2000012472A3 (en) Process for preparing certain phenyl urea compounds
GR1002687B (el) Διαδικασια παραγωγης.